Kevin Sheng Hsiang Fang: Final Debarment Order, 91408-91409 [2024-26917]
Download as PDF
ddrumheller on DSK120RN23PROD with NOTICES1
91408
Federal Register / Vol. 89, No. 223 / Tuesday, November 19, 2024 / Notices
to participate in the CDAD clinical trial,
received and taken the study
medication, provided stool samples,
completed the required documents and
journals, and participated in
assessments conducted by the clinical
investigator. In addition, Ms. Portela
Martinez knew that 10 or more
individuals’ means of identification
were used unlawfully or without
authority in furtherance of the
conspiracy. Specifically, Ms. Portela
Martinez, along with some of her coconspirators, used the means of
identification of real persons, to create
subject identification numbers for those
persons, and then used those subject
identification numbers to falsely portray
the persons as legitimate subjects in the
CDAD clinical trial, when in fact they
were not. In addition, Ms. Portela
Martinez along with her co-conspirators
submitted her own stool and blood
samples to make it appear as if they
came from study participants.
Furthermore, Ms. Portela Martinez
was one of only two individuals who
inputted CDAD clinical trial data in the
Almac Clinical Technology Integrated
Response Technology database (Almac
database). The information in the Almac
database was the foundation for all
subsequent subject CDAD clinical trial
data. Ms. Portela Martinez repeatedly
entered false and fabricated subject
screening and randomization
information in the Almac database.
Ms. Portela Martinez received $19,620
in proceeds for the CDAD clinical trial.
AMB received over $277,000 for the
CDAD clinical trial.
FDA sent Ms. Portela Martinez, by
certified mail, on August 12, 2024, a
notice proposing to permanently debar
her from providing services in any
capacity to a person that has an
approved or pending drug product
application. The proposal was based on
a finding, under section 306(a)(2)(A) of
the FD&C Act, that Ms. Portela Martinez
was convicted of a felony under Federal
law for conduct relating to the
development or approval, including the
process of development or approval, of
any drug product. The proposal
informed Ms. Portela Martinez of the
proposed debarment and offered her an
opportunity to request a hearing,
providing her 30 days from the date of
receipt of the letter in which to file the
request, and advised her that failure to
request a hearing constituted a waiver of
the opportunity for a hearing and of any
contentions concerning this action. Ms.
Portela Martinez received the proposal
and notice of opportunity for a hearing
on August 15, 2024. Ms. Portela
Martinez failed to request a hearing
within the timeframe prescribed by
VerDate Sep<11>2014
17:42 Nov 18, 2024
Jkt 265001
regulation and has, therefore, waived
her opportunity for a hearing and
waived any contentions concerning her
debarment (21 CFR part 12).
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
II. Findings and Order
[Docket No. FDA–2024–N–1178]
Therefore, the Division of Field
Enforcement Director, Office of
Inspections and Investigations, under
section 306(a)(2)(A) of the FD&C Act,
under authority delegated to the
Division of Field Enforcement Director,
finds that Ms. Ivette Maria Portela
Martinez has been convicted of a felony
under Federal law for conduct relating
to the development or approval,
including the process of development or
approval, of any drug product.
As a result of the foregoing finding,
Ms. Portela Martinez is permanently
debarred from providing services in any
capacity to a person with an approved
or pending drug product application,
effective (see DATES) (see sections
306(a)(2)(A) and 306(c)(2)(A)(ii) of the
FD&C Act). Any person with an
approved or pending drug product
application who knowingly employs or
retains as a consultant or contractor, or
otherwise uses in any capacity the
services of Ms. Portela Martinez during
her debarment, will be subject to civil
money penalties (section 307(a)(6) of the
FD&C Act (21 U.S.C. 335b(a)(6))). If Ms.
Portela Martinez provides services in
any capacity to a person with an
approved or pending drug product
application during her period of
debarment, she will be subject to civil
money penalties (section 307(a)(7) of the
FD&C Act). In addition, FDA will not
accept or review any abbreviated new
drug application from Ms. Portela
Martinez during her period of
debarment, other than in connection
with an audit under section 306 of the
FD&C Act (section 306(c)(1)(B) of the
FD&C Act). Note that, for purposes of
sections 306 and 307 of the FD&C Act,
a ‘‘drug product’’ is defined as a ‘‘drug
subject to regulation under section 505,
512, or 802 of the FD&C Act [(21 U.S.C.
355, 360b, 382)] or under section 351 of
the Public Health Service Act [(42
U.S.C. 262)]’’ (section 201(dd) of the
FD&C Act (21 U.S.C. 321(dd))).
Kevin Sheng Hsiang Fang: Final
Debarment Order
Dated: November 7, 2024.
Kimberlee Trzeciak,
Deputy Commissioner for Policy, Legislation,
and International Affairs.
[FR Doc. 2024–26912 Filed 11–18–24; 8:45 am]
BILLING CODE 4164–01–P
PO 00000
Frm 00096
Fmt 4703
Sfmt 4703
Food and Drug Administration
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug
Administration (FDA) is issuing an
order under the Federal Food, Drug, and
Cosmetic Act (FD&C Act) debarring
Kevin Sheng Hsiang Fang for a period
of 5 years from importing articles of
food or offering such articles for
importation into the United States. FDA
bases this order on a finding that Mr.
Fang was convicted of a felony count
under Federal law for conduct relating
to the importation into the United States
of an article of food. Mr. Fang was given
notice of the proposed debarment and
an opportunity to request a hearing
within the timeframe prescribed by
regulation. As of July 1, 2024 (30 days
after receipt of the notice), Mr. Fang has
not responded. Mr. Fang’s failure to
respond and request a hearing
constitutes a waiver of Mr. Fang’s right
to a hearing concerning this matter.
DATES: This order is applicable
November 19, 2024.
ADDRESSES: Any application by Mr.
Fang for termination of debarment
under section 306(d)(1) of the FD&C Act
(21 U.S.C. 335a(d)(1)) may be submitted
at any time as follows:
SUMMARY:
Electronic Submissions
• Federal eRulemaking Portal:
https://www.regulations.gov. Follow the
instructions for submitting comments.
An application submitted electronically,
including attachments, to https://
www.regulations.gov will be posted to
the docket unchanged. Because your
application will be made public, you are
solely responsible for ensuring that your
application does not include any
confidential information that you or a
third party may not wish to be posted,
such as medical information, your or
anyone else’s Social Security number, or
confidential business information, such
as a manufacturing process. Please note
that if you include your name, contact
information, or other information that
identifies you in the body of your
application, that information will be
posted on https://www.regulations.gov.
• If you want to submit an
application with confidential
information that you do not wish to be
made available to the public, submit the
E:\FR\FM\19NON1.SGM
19NON1
Federal Register / Vol. 89, No. 223 / Tuesday, November 19, 2024 / Notices
ddrumheller on DSK120RN23PROD with NOTICES1
application as a written/paper
submission and in the manner detailed
(see ‘‘Written/Paper Submissions’’ and
‘‘Instructions’’).
Written/Paper Submissions
• Mail/Hand Delivery/Courier (for
written/paper submissions): Dockets
Management Staff (HFA–305), Food and
Drug Administration, 5630 Fishers
Lane, Rm. 1061, Rockville, MD 20852.
• For a written/paper application
submitted to the Dockets Management
Staff, FDA will post your application, as
well as any attachments, except for
information submitted, marked, and
identified, as confidential, if submitted
as detailed in ‘‘Instructions.’’
Instructions: All applications must
include the Docket No. FDA–2024–N–
1178. Received applications will be
placed in the docket and, except for
those submitted as ‘‘Confidential
Submissions,’’ publicly viewable at
https://www.regulations.gov or at the
Dockets Management Staff between 9
a.m. and 4 p.m., Monday through
Friday, 240–402–7500.
• Confidential Submissions—To
submit an application with confidential
information that you do not wish to be
made publicly available, submit your
application only as a written/paper
submission. You should submit two
copies total. One copy will include the
information you claim to be confidential
with a heading or cover note that states
‘‘THIS DOCUMENT CONTAINS
CONFIDENTIAL INFORMATION.’’ The
Agency will review this copy, including
the claimed confidential information, in
its consideration of your application.
The second copy, which will have the
claimed confidential information
redacted/blacked out, will be available
for public viewing and posted on
https://www.regulations.gov. Submit
both copies to the Dockets Management
Staff. Any information marked as
‘‘confidential’’ will not be disclosed
except in accordance with 21 CFR 10.20
and other applicable disclosure law. For
more information about FDA’s posting
of comments to public dockets, see 80
FR 56469, September 18, 2015, or access
the information at: https://
www.govinfo.gov/content/pkg/FR-201509-18/pdf/2015-23389.pdf.
Docket: For access to the docket, go to
https://www.regulations.gov and insert
the docket number, found in brackets in
the heading of this document, into the
‘‘Search’’ box and follow the prompts
and/or go to the Dockets Management
Staff, 5630 Fishers Lane, Rm. 1061,
Rockville, MD 20852 between 9 a.m.
and 4 p.m., Monday through Friday,
240–402–7500. Publicly available
submissions may be seen in the docket.
VerDate Sep<11>2014
17:42 Nov 18, 2024
Jkt 265001
FOR FURTHER INFORMATION CONTACT:
Jaime Espinosa, Division of Field
Enforcement, Office of Field Regulatory
Operations, Office of Inspections and
Investigations, Food and Drug
Administration, 240–402–8743, or
debarments@fda.hhs.gov.
SUPPLEMENTARY INFORMATION:
I. Background
Section 306(b)(1)(C) of the FD&C Act
permits FDA to debar an individual
from importing an article of food or
offering such an article for import into
the United States if FDA finds, as
required by section 306(b)(3)(A) of the
FD&C Act, that the individual has been
convicted of a felony for conduct
relating to the importation into the
United States of any food.
On February 26, 2024, Mr. Fang was
convicted as defined in section
306(l)(1)(A) of the FD&C Act, in the U.
S. District Court for the Central District
of California, when the court entered
judgment against him, after his plea of
guilty, to the offense of importing
merchandise contrary to law in
violation of 18 U.S.C. 545 and 18 U.S.C.
2(b). The underlying facts supporting
the conviction are as follows: As
contained in the information from his
case, Mr. Fang worked as a manager at
a company called Heng Xing Foods,
Inc., which was a business entity that
imported shipments of Chinese roasted
eel as a food wholesaler. Mr. Fang also
imported shipments of Chinese roasted
eel as a food wholesaler and did
business as Young Chang Trading Co.,
Ltd. in or about October 16, 2017, in Los
Angeles County. Mr. Fang knowingly
and fraudulently imported and brought,
and willfully caused to be imported and
brought, Chinese roasted eel adulterated
with Gentian Violet and Leucogentian
Violent, both being new unsafe animal
drugs, into the United States and
contrary to law.
As a result of this conviction, FDA
sent Mr. Fang, by certified mail, on May
29, 2024, a notice proposing to debar
him for a 5-year period from importing
articles of food or offering such articles
for import into the United States. The
proposal was based on a finding under
section 306(b)(1)(C) of the FD&C Act
that Mr. Fang’s felony conviction under
Federal law for importing merchandise
contrary to law in violation of 18 U.S.C.
545 and 18 U.S.C. 2(b), was for conduct
relating to the importation into the
United States of an article of food
because the offense involved Mr. Fang
and his company importing roasted eel
adulterated with Gentian Violet and
Leucogentian Violent, both being new
unsafe animal drugs. In proposing a
debarment period, FDA weighed the
PO 00000
Frm 00097
Fmt 4703
Sfmt 9990
91409
considerations set forth in section
306(c)(3) of the FD&C Act that it
considered applicable to Mr. Fang’s
offense and concluded that the offense
warranted the imposition of a 5-year
period of debarment.
The proposal informed Mr. Fang of
the proposed debarment and offered
him an opportunity to request a hearing,
providing him 30 days from the date of
receipt of the letter in which to file the
request, and advised him that failure to
request a hearing constituted a waiver of
the opportunity for a hearing and of any
contentions concerning this action. Mr.
Fang received the proposal and notice of
opportunity for a hearing on June 1,
2024. Mr. Fang failed to request a
hearing within the timeframe prescribed
by regulation and has, therefore, waived
his opportunity for a hearing and
waived any contentions concerning his
debarment (21 CFR part 12).
II. Findings and Order
Therefore, the Division of Field
Enforcement Director, Office of
Inspections and Investigations, under
section 306(b)(1)(C) of the FD&C Act,
under authority delegated to the
Division of Field Enforcement Director,
finds that Mr. Kevin Sheng Hsiang Fang
has been convicted of a felony under
Federal law for conduct relating to the
importation into the United States of an
article of food and that he is subject to
a 5-year period of debarment. FDA finds
that the offense should be accorded a
debarment period of 5 years as provided
by section 306(c)(2)(A)(iii) of the FD&C
Act.
As a result of the foregoing finding,
Mr. Fang is debarred for a period of 5
years from importing articles of food or
offering such articles for import into the
United States, effective (see DATES).
Pursuant to section 301(cc) of the FD&C
Act (21 U.S.C. 331(cc)), the importing or
offering for import into the United
States of an article of food by, with the
assistance of, or at the direction of Mr.
Fang is a prohibited act.
Dated: November 7, 2024.
Kimberlee Trzeciak,
Deputy Commissioner for Policy, Legislation,
and International Affairs.
[FR Doc. 2024–26917 Filed 11–18–24; 8:45 am]
BILLING CODE 4164–01–P
E:\FR\FM\19NON1.SGM
19NON1
Agencies
[Federal Register Volume 89, Number 223 (Tuesday, November 19, 2024)]
[Notices]
[Pages 91408-91409]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-26917]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2024-N-1178]
Kevin Sheng Hsiang Fang: Final Debarment Order
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is issuing an order
under the Federal Food, Drug, and Cosmetic Act (FD&C Act) debarring
Kevin Sheng Hsiang Fang for a period of 5 years from importing articles
of food or offering such articles for importation into the United
States. FDA bases this order on a finding that Mr. Fang was convicted
of a felony count under Federal law for conduct relating to the
importation into the United States of an article of food. Mr. Fang was
given notice of the proposed debarment and an opportunity to request a
hearing within the timeframe prescribed by regulation. As of July 1,
2024 (30 days after receipt of the notice), Mr. Fang has not responded.
Mr. Fang's failure to respond and request a hearing constitutes a
waiver of Mr. Fang's right to a hearing concerning this matter.
DATES: This order is applicable November 19, 2024.
ADDRESSES: Any application by Mr. Fang for termination of debarment
under section 306(d)(1) of the FD&C Act (21 U.S.C. 335a(d)(1)) may be
submitted at any time as follows:
Electronic Submissions
Federal eRulemaking Portal: https://www.regulations.gov.
Follow the instructions for submitting comments. An application
submitted electronically, including attachments, to https://www.regulations.gov will be posted to the docket unchanged. Because
your application will be made public, you are solely responsible for
ensuring that your application does not include any confidential
information that you or a third party may not wish to be posted, such
as medical information, your or anyone else's Social Security number,
or confidential business information, such as a manufacturing process.
Please note that if you include your name, contact information, or
other information that identifies you in the body of your application,
that information will be posted on https://www.regulations.gov.
If you want to submit an application with confidential
information that you do not wish to be made available to the public,
submit the
[[Page 91409]]
application as a written/paper submission and in the manner detailed
(see ``Written/Paper Submissions'' and ``Instructions'').
Written/Paper Submissions
Mail/Hand Delivery/Courier (for written/paper
submissions): Dockets Management Staff (HFA-305), Food and Drug
Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.
For a written/paper application submitted to the Dockets
Management Staff, FDA will post your application, as well as any
attachments, except for information submitted, marked, and identified,
as confidential, if submitted as detailed in ``Instructions.''
Instructions: All applications must include the Docket No. FDA-
2024-N-1178. Received applications will be placed in the docket and,
except for those submitted as ``Confidential Submissions,'' publicly
viewable at https://www.regulations.gov or at the Dockets Management
Staff between 9 a.m. and 4 p.m., Monday through Friday, 240-402-7500.
Confidential Submissions--To submit an application with
confidential information that you do not wish to be made publicly
available, submit your application only as a written/paper submission.
You should submit two copies total. One copy will include the
information you claim to be confidential with a heading or cover note
that states ``THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION.'' The
Agency will review this copy, including the claimed confidential
information, in its consideration of your application. The second copy,
which will have the claimed confidential information redacted/blacked
out, will be available for public viewing and posted on https://www.regulations.gov. Submit both copies to the Dockets Management
Staff. Any information marked as ``confidential'' will not be disclosed
except in accordance with 21 CFR 10.20 and other applicable disclosure
law. For more information about FDA's posting of comments to public
dockets, see 80 FR 56469, September 18, 2015, or access the information
at: https://www.govinfo.gov/content/pkg/FR-2015-09-18/pdf/2015-23389.pdf.
Docket: For access to the docket, go to https://www.regulations.gov
and insert the docket number, found in brackets in the heading of this
document, into the ``Search'' box and follow the prompts and/or go to
the Dockets Management Staff, 5630 Fishers Lane, Rm. 1061, Rockville,
MD 20852 between 9 a.m. and 4 p.m., Monday through Friday, 240-402-
7500. Publicly available submissions may be seen in the docket.
FOR FURTHER INFORMATION CONTACT: Jaime Espinosa, Division of Field
Enforcement, Office of Field Regulatory Operations, Office of
Inspections and Investigations, Food and Drug Administration, 240-402-
8743, or [email protected].
SUPPLEMENTARY INFORMATION:
I. Background
Section 306(b)(1)(C) of the FD&C Act permits FDA to debar an
individual from importing an article of food or offering such an
article for import into the United States if FDA finds, as required by
section 306(b)(3)(A) of the FD&C Act, that the individual has been
convicted of a felony for conduct relating to the importation into the
United States of any food.
On February 26, 2024, Mr. Fang was convicted as defined in section
306(l)(1)(A) of the FD&C Act, in the U. S. District Court for the
Central District of California, when the court entered judgment against
him, after his plea of guilty, to the offense of importing merchandise
contrary to law in violation of 18 U.S.C. 545 and 18 U.S.C. 2(b). The
underlying facts supporting the conviction are as follows: As contained
in the information from his case, Mr. Fang worked as a manager at a
company called Heng Xing Foods, Inc., which was a business entity that
imported shipments of Chinese roasted eel as a food wholesaler. Mr.
Fang also imported shipments of Chinese roasted eel as a food
wholesaler and did business as Young Chang Trading Co., Ltd. in or
about October 16, 2017, in Los Angeles County. Mr. Fang knowingly and
fraudulently imported and brought, and willfully caused to be imported
and brought, Chinese roasted eel adulterated with Gentian Violet and
Leucogentian Violent, both being new unsafe animal drugs, into the
United States and contrary to law.
As a result of this conviction, FDA sent Mr. Fang, by certified
mail, on May 29, 2024, a notice proposing to debar him for a 5-year
period from importing articles of food or offering such articles for
import into the United States. The proposal was based on a finding
under section 306(b)(1)(C) of the FD&C Act that Mr. Fang's felony
conviction under Federal law for importing merchandise contrary to law
in violation of 18 U.S.C. 545 and 18 U.S.C. 2(b), was for conduct
relating to the importation into the United States of an article of
food because the offense involved Mr. Fang and his company importing
roasted eel adulterated with Gentian Violet and Leucogentian Violent,
both being new unsafe animal drugs. In proposing a debarment period,
FDA weighed the considerations set forth in section 306(c)(3) of the
FD&C Act that it considered applicable to Mr. Fang's offense and
concluded that the offense warranted the imposition of a 5-year period
of debarment.
The proposal informed Mr. Fang of the proposed debarment and
offered him an opportunity to request a hearing, providing him 30 days
from the date of receipt of the letter in which to file the request,
and advised him that failure to request a hearing constituted a waiver
of the opportunity for a hearing and of any contentions concerning this
action. Mr. Fang received the proposal and notice of opportunity for a
hearing on June 1, 2024. Mr. Fang failed to request a hearing within
the timeframe prescribed by regulation and has, therefore, waived his
opportunity for a hearing and waived any contentions concerning his
debarment (21 CFR part 12).
II. Findings and Order
Therefore, the Division of Field Enforcement Director, Office of
Inspections and Investigations, under section 306(b)(1)(C) of the FD&C
Act, under authority delegated to the Division of Field Enforcement
Director, finds that Mr. Kevin Sheng Hsiang Fang has been convicted of
a felony under Federal law for conduct relating to the importation into
the United States of an article of food and that he is subject to a 5-
year period of debarment. FDA finds that the offense should be accorded
a debarment period of 5 years as provided by section 306(c)(2)(A)(iii)
of the FD&C Act.
As a result of the foregoing finding, Mr. Fang is debarred for a
period of 5 years from importing articles of food or offering such
articles for import into the United States, effective (see DATES).
Pursuant to section 301(cc) of the FD&C Act (21 U.S.C. 331(cc)), the
importing or offering for import into the United States of an article
of food by, with the assistance of, or at the direction of Mr. Fang is
a prohibited act.
Dated: November 7, 2024.
Kimberlee Trzeciak,
Deputy Commissioner for Policy, Legislation, and International Affairs.
[FR Doc. 2024-26917 Filed 11-18-24; 8:45 am]
BILLING CODE 4164-01-P